PLI scheme envisages manufacturing of 41 Bulk Drugs with a total outlay of Rs. 6,940 cr. during the tenure of the scheme from 2020-21 to 2029-30
ICMR’s budgetary allowance has increased by 4-fold in the past 10 years, showcasing our commitment towards Health Research
Clinical findings support the safety and efficacy of BMND08 at a maximum dosage of 12mg
This newly set up Centre for bio-analytical testing has already received European Regulatory Authority clearance recently
The production started from its greenfield manufacturing facility at Aurangabad in Maharashtra
Cipla completes transfer of Generics Business Undertaking
The overall transaction is expected to conclude over next 12-15 months subject to receipt of all relevant shareholder and regulatory approvals
The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA
Subscribe To Our Newsletter & Stay Updated